Personalis Publishes ctDNA Study Showing 98% Detection Rate in Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: Newsfilter
- Significant Research Findings: Personalis's study published in Clinical Cancer Research reveals that its ultra-sensitive tumor-informed molecular residual disease (MRD) assay, NeXT Personal®, achieved a 98% baseline ctDNA detection rate in 202 stage IV solid tumor patients, demonstrating its effectiveness and reliability across diverse cancer types.
- Clear Prognostic Indicators: The study indicates that patients showing early decreases in ctDNA levels during immunotherapy had significantly improved overall survival rates, while those with rising ctDNA levels exhibited a zero percent overall response rate, underscoring the importance of ctDNA dynamics in cancer treatment monitoring.
- Durable Clearance Predicts Survival: Patients achieving durable molecular clearance (negative ctDNA for at least 180 days) had a 100% overall survival rate in the study, providing strong clinical support for the assay's application and potentially transforming management strategies for late-stage cancer patients.
- Vast Technical Potential: Rich Chen, M.D., CMO of Personalis, emphasized that this study highlights the broad potential of ultrasensitive ctDNA testing in both early and late-stage cancers, which could drive a new paradigm in personalized cancer management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSNL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSNL
Wall Street analysts forecast PSNL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSNL is 11.17 USD with a low forecast of 10.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.970
Low
10.00
Averages
11.17
High
12.00
Current: 9.970
Low
10.00
Averages
11.17
High
12.00
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Personalis to Attend BTIG MedTech Conference
- Management Attendance: Personalis, Inc.'s management team will attend the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026, at the Cliff Lodge in Snowbird, Utah, aiming to showcase the company's leadership in precision oncology.
- Precision Oncology Innovation: Personalis is transforming cancer management through breakthrough personalized testing, combining tumor and normal profiling to deliver advanced insights that adapt as cancer evolves, thereby enhancing patient treatment outcomes.
- Product Advantages: The company's products focus on detecting minimal residual disease (MRD) and recurrence at the earliest timepoints, enabling targeted therapy selection based on ultra-comprehensive genomic profiling, which enhances biomarker strategies for drug development and strengthens market competitiveness.
- Company Background: Based in Fremont, California, Personalis is dedicated to reshaping cancer management paradigms through personalized testing, guiding care from biopsy through the patient's entire lifecycle.
Continue Reading
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
- AI Infrastructure Boost: ARK Invest increased positions in semiconductor companies like AMD, Broadcom, and TSMC, signaling strong confidence in the infrastructure for AI workloads, which is expected to drive long-term growth for these firms.
- Gene Editing Investments: The firm added 196K shares of Intellia Therapeutics and 49K shares of 10x Genomics, continuing to focus on next-generation sequencing and in vivo gene editing, aiming to capture innovative opportunities in the biotech sector.
- Autonomous Driving Focus: ARK invested in companies like WeRide and Pony AI in the autonomous driving and robotics space, reinforcing its strategic positioning in future transportation technologies, which is likely to enhance portfolio diversity and potential returns.
- Trimmed Mature Tech Holdings: ARK sold over 86K shares of Tesla worth more than $37 million and reduced stakes in Unity Software, reflecting a cautious stance on mature tech companies that may impact short-term stock performance.
Continue Reading